Biogen Inc Cmn (BIIB) 314.81 $BIIB Stock Market
Post# of 273391
Posted On: 09/22/2016 7:17:04 PM
Biogen Inc Cmn (BIIB) 314.81 $BIIB
Stock Market News for September 21, 2016
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:22AM CDT
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
FDX: 173.66 (-0.20), AGN: 243.43 (+5.02), PBR: 9.56 (+0.05), BIIB: 314.81 (+2.81), SON: 53.50 (+0.46), GILD: 81.52 (-0.18), FB: 130.08 (+0.14), XOM: 83.54 (+0.24), AMGN: 175.62 (+1.77), KBH: 15.65 (+0.42), TBRA: 39.50 (+0.42)
Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug
Arpita Dutt - Zacks Investment Research - Wed Sep 21, 7:39AM CDT
The biotech sector got a boost with Allergan announcing its intention to acquire Tobira as well as a couple of other companies.
BIIB: 314.81 (+2.81), VRTX: 92.12 (+0.30), GERN: 2.22 (-0.03), SRPT: 60.97 (+4.75), TBRA: 39.50 (+0.42), ALKS: 51.00 (+0.52), REGN: 408.01 (+1.49)
Biogen Idec Has Returned 23.9% Since SmarTrend Recommendation (BIIB)
Comtex SmarTrend(R) - Tue Sep 20, 1:00PM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 3 months, Biogen Idec has returned 23.93% as of today's recent price of $306.65.
BIIB: 314.81 (+2.81)
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 1.70% Rise
Comtex SmarTrend(R) - Tue Sep 20, 12:16PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $304.00 to a high of $308.67. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $308.00 on volume of 552,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 314.81 (+2.81)
New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA(TM) (Daclizumab) and Support Long-Term Safety Profile
BusinessWire - Thu Sep 15, 6:30AM CDT
--Interim Analysis of EXTEND Study Shows Sustained ZINBRYTA Efficacy for Up to Five Years
BIIB: 314.81 (+2.81), ABBV: 65.08 (+0.98)
Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016
BusinessWire - Wed Sep 14, 3:01PM CDT
Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2016 financial results on Wednesday, October 26, 2016, before the financial markets open.
BIIB: 314.81 (+2.81)
Biotech Stock Roundup: Horizon-Raptor Acquisition Deal, Geron Down on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Sep 14, 7:47AM CDT
With the Horizon-Raptor acquisition deal being announced, will the biotech sector see more such merger and acquisition announcements?
BIIB: 314.81 (+2.81), RPTP: 8.96 (-0.03), LXRX: 18.82 (-0.08), GILD: 81.52 (-0.18), GERN: 2.22 (-0.03), HZNP: 19.41 (+0.24), SPPI: 4.81 (+0.34)
New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA(R) in Both Clinical Studies and Real-World Setting
BusinessWire - Wed Sep 14, 6:30AM CDT
--a^' Benefit-Risk Profile of TECFIDERA Remains Favorable Up to Nine Years a^'
BIIB: 314.81 (+2.81)
Perrigo Up as Starboard Reveals Stake, Changes Proposed
Zacks Equity Research - Zacks Investment Research - Tue Sep 13, 3:30PM CDT
Perrigo's (PRGO) shares gained after the activist investor, Starboard, disclosed in a letter its 4.6% stake in the company, and prompted it to take immediate steps.
BIIB: 314.81 (+2.81), PRGO: 97.12 (+3.43), GERN: 2.22 (-0.03), MYL: 42.59 (+0.68)
Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Zacks Equity Research - Zacks Investment Research - Tue Sep 13, 8:12AM CDT
Media and political focus on the high prices of drugs have made things difficult for the pharma/biotech sector since the past one year.
ABT: 42.22 (+0.30), BIIB: 314.81 (+2.81), VNDA: 16.62 (+1.06), PFE: 34.15 (-0.13), AMGN: 175.62 (+1.77), AEGR: 2.65 (+0.33), LLY: 81.29 (+0.42), PDLI: 3.35 (-0.01), JNJ: 119.46 (+0.55), GILD: 81.52 (-0.18), AZN: 34.28 (+0.53), MRK: 63.02 (+0.32), SNY: 38.57 (+0.19), NVS: 82.03 (+0.51)
Biogen Idec Shares Up 22.3% Since SmarTrend's Buy Recommendation (BIIB)
Comtex SmarTrend(R) - Tue Sep 13, 1:03AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 2 months, Biogen Idec has returned 22.32% as of today's recent price of $302.66.
BIIB: 314.81 (+2.81)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 2.40%
Comtex SmarTrend(R) - Fri Sep 09, 12:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.09 to a high of $305.48. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $307.42 on volume of 870,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 314.81 (+2.81)
Biogen Idec Falls 2.40% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Sep 09, 12:57PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.09 to a high of $305.48. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $307.42 on volume of 870,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 314.81 (+2.81)
Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio
BusinessWire - Thu Sep 08, 6:30AM CDT
--Comparative Effectiveness Studies Reinforce Clinical Data Supporting the Strong, Sustained Efficacy of TECFIDERA(R)
BIIB: 314.81 (+2.81), ACOR: 27.22 (+0.15)
These Stocks are Predicted to Outperform this Week According to Forcerank
ESTMZ - Wed Sep 07, 10:10AM CDT
Each week Forcerank runs a variety of games covering different industries. What we have found, is that the highest ranked companies in their respective games deliver the greatest positive price movement for that week. This week the winners include...
UA: 39.90 (+0.29), TSLA: 206.43 (+1.21), BIIB: 314.81 (+2.81), AMZN: 804.70 (+14.96), SPY: 217.18 (+1.36), FB: 130.08 (+0.14), XOM: 83.54 (+0.24), AAPL: 114.62 (+1.07)
Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled
Arpita Dutt - Zacks Investment Research - Wed Sep 07, 8:30AM CDT
Although it was a relatively slow week for the biotech sector, companies like CoLucid (CLCD) and Dynavax were in the news with pipeline updates.
DVAX: 11.62 (-0.05), BIIB: 314.81 (+2.81), CLCD: 31.06 (-2.15), BMRN: 97.45 (-0.12), ALXN: 133.69 (+3.33), AMGN: 175.62 (+1.77), SPPI: 4.81 (+0.34)
Research Reports Coverage on Biotech Stocks -- Biogen, ImmunoGen, Jazz Pharma, and Cempra
PR Newswire - Wed Sep 07, 7:05AM CDT
The Biotech arena took a beating at the start of this year, but recent major takeovers have started drawing investors' interests back toward the industry. Stock-Callers.com shifts investors' attention to these four equities and see if they are positioned for long-term growth: Biogen Inc. (NASDAQ: BIIB), ImmunoGen Inc. (NASDAQ: IMGN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Cempra Inc. (NASDAQ: CEMP). These stocks research reports can be downloaded now by simply registering for free at:
BIIB: 314.81 (+2.81), JAZZ: 126.65 (-2.16), IMGN: 2.87 (-0.01), CEMP: 24.60 (-0.01)
Stock Market News for September 21, 2016
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:22AM CDT
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
FDX: 173.66 (-0.20), AGN: 243.43 (+5.02), PBR: 9.56 (+0.05), BIIB: 314.81 (+2.81), SON: 53.50 (+0.46), GILD: 81.52 (-0.18), FB: 130.08 (+0.14), XOM: 83.54 (+0.24), AMGN: 175.62 (+1.77), KBH: 15.65 (+0.42), TBRA: 39.50 (+0.42)
Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug
Arpita Dutt - Zacks Investment Research - Wed Sep 21, 7:39AM CDT
The biotech sector got a boost with Allergan announcing its intention to acquire Tobira as well as a couple of other companies.
BIIB: 314.81 (+2.81), VRTX: 92.12 (+0.30), GERN: 2.22 (-0.03), SRPT: 60.97 (+4.75), TBRA: 39.50 (+0.42), ALKS: 51.00 (+0.52), REGN: 408.01 (+1.49)
Biogen Idec Has Returned 23.9% Since SmarTrend Recommendation (BIIB)
Comtex SmarTrend(R) - Tue Sep 20, 1:00PM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 3 months, Biogen Idec has returned 23.93% as of today's recent price of $306.65.
BIIB: 314.81 (+2.81)
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 1.70% Rise
Comtex SmarTrend(R) - Tue Sep 20, 12:16PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $304.00 to a high of $308.67. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $308.00 on volume of 552,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 314.81 (+2.81)
New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA(TM) (Daclizumab) and Support Long-Term Safety Profile
BusinessWire - Thu Sep 15, 6:30AM CDT
--Interim Analysis of EXTEND Study Shows Sustained ZINBRYTA Efficacy for Up to Five Years
BIIB: 314.81 (+2.81), ABBV: 65.08 (+0.98)
Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016
BusinessWire - Wed Sep 14, 3:01PM CDT
Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2016 financial results on Wednesday, October 26, 2016, before the financial markets open.
BIIB: 314.81 (+2.81)
Biotech Stock Roundup: Horizon-Raptor Acquisition Deal, Geron Down on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Sep 14, 7:47AM CDT
With the Horizon-Raptor acquisition deal being announced, will the biotech sector see more such merger and acquisition announcements?
BIIB: 314.81 (+2.81), RPTP: 8.96 (-0.03), LXRX: 18.82 (-0.08), GILD: 81.52 (-0.18), GERN: 2.22 (-0.03), HZNP: 19.41 (+0.24), SPPI: 4.81 (+0.34)
New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA(R) in Both Clinical Studies and Real-World Setting
BusinessWire - Wed Sep 14, 6:30AM CDT
--a^' Benefit-Risk Profile of TECFIDERA Remains Favorable Up to Nine Years a^'
BIIB: 314.81 (+2.81)
Perrigo Up as Starboard Reveals Stake, Changes Proposed
Zacks Equity Research - Zacks Investment Research - Tue Sep 13, 3:30PM CDT
Perrigo's (PRGO) shares gained after the activist investor, Starboard, disclosed in a letter its 4.6% stake in the company, and prompted it to take immediate steps.
BIIB: 314.81 (+2.81), PRGO: 97.12 (+3.43), GERN: 2.22 (-0.03), MYL: 42.59 (+0.68)
Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Zacks Equity Research - Zacks Investment Research - Tue Sep 13, 8:12AM CDT
Media and political focus on the high prices of drugs have made things difficult for the pharma/biotech sector since the past one year.
ABT: 42.22 (+0.30), BIIB: 314.81 (+2.81), VNDA: 16.62 (+1.06), PFE: 34.15 (-0.13), AMGN: 175.62 (+1.77), AEGR: 2.65 (+0.33), LLY: 81.29 (+0.42), PDLI: 3.35 (-0.01), JNJ: 119.46 (+0.55), GILD: 81.52 (-0.18), AZN: 34.28 (+0.53), MRK: 63.02 (+0.32), SNY: 38.57 (+0.19), NVS: 82.03 (+0.51)
Biogen Idec Shares Up 22.3% Since SmarTrend's Buy Recommendation (BIIB)
Comtex SmarTrend(R) - Tue Sep 13, 1:03AM CDT
SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on July 7th, 2016 at $247.44. In approximately 2 months, Biogen Idec has returned 22.32% as of today's recent price of $302.66.
BIIB: 314.81 (+2.81)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 2.40%
Comtex SmarTrend(R) - Fri Sep 09, 12:59PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.09 to a high of $305.48. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $307.42 on volume of 870,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 314.81 (+2.81)
Biogen Idec Falls 2.40% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Sep 09, 12:57PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.09 to a high of $305.48. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $307.42 on volume of 870,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 314.81 (+2.81)
Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio
BusinessWire - Thu Sep 08, 6:30AM CDT
--Comparative Effectiveness Studies Reinforce Clinical Data Supporting the Strong, Sustained Efficacy of TECFIDERA(R)
BIIB: 314.81 (+2.81), ACOR: 27.22 (+0.15)
These Stocks are Predicted to Outperform this Week According to Forcerank
ESTMZ - Wed Sep 07, 10:10AM CDT
Each week Forcerank runs a variety of games covering different industries. What we have found, is that the highest ranked companies in their respective games deliver the greatest positive price movement for that week. This week the winners include...
UA: 39.90 (+0.29), TSLA: 206.43 (+1.21), BIIB: 314.81 (+2.81), AMZN: 804.70 (+14.96), SPY: 217.18 (+1.36), FB: 130.08 (+0.14), XOM: 83.54 (+0.24), AAPL: 114.62 (+1.07)
Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled
Arpita Dutt - Zacks Investment Research - Wed Sep 07, 8:30AM CDT
Although it was a relatively slow week for the biotech sector, companies like CoLucid (CLCD) and Dynavax were in the news with pipeline updates.
DVAX: 11.62 (-0.05), BIIB: 314.81 (+2.81), CLCD: 31.06 (-2.15), BMRN: 97.45 (-0.12), ALXN: 133.69 (+3.33), AMGN: 175.62 (+1.77), SPPI: 4.81 (+0.34)
Research Reports Coverage on Biotech Stocks -- Biogen, ImmunoGen, Jazz Pharma, and Cempra
PR Newswire - Wed Sep 07, 7:05AM CDT
The Biotech arena took a beating at the start of this year, but recent major takeovers have started drawing investors' interests back toward the industry. Stock-Callers.com shifts investors' attention to these four equities and see if they are positioned for long-term growth: Biogen Inc. (NASDAQ: BIIB), ImmunoGen Inc. (NASDAQ: IMGN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Cempra Inc. (NASDAQ: CEMP). These stocks research reports can be downloaded now by simply registering for free at:
BIIB: 314.81 (+2.81), JAZZ: 126.65 (-2.16), IMGN: 2.87 (-0.01), CEMP: 24.60 (-0.01)
(0)
(0)